Menu
Search
Search
Customer Service
The highly experienced Zephex® team provide a comprehensive range of key support services to customers as an integral part of our offering, including:
- In addition to our own Certificate of Analysis, if required we can facilitate completely independent customer “acceptance testing” to analyse shipments before they are despatched.
- Support in complying with ICH guidelines as confirmed by inspection bodies such as the FDA and MHRA, and in meeting other legislation such as the European F-Gas regulations.
- Skilled analytical and transport engineering services to assist in the specification, design, installation and validation of propellant storage and handling facilities.
- A range of technical support including formulation advice, full regulatory documentation support and analytical methods.
Innovation
Koura has developed a new, innovative low global warming potential (GWP) medical propellant, introducing Zephex 152a.
Zephex® 152a will reduce the carbon footprint of pressurised metered dose inhalers, bringing about a greater than 90 percent reduction in GWP compared to some current MDI propellants. This will mean over 100 million people with respiratory conditions such as asthma can address any concerns over the carbon footprint of their asthma inhaler.
From the Newsroom
RDD 2022 Recap: 152a features across event agenda
2022 is a significant year for 152a (Zephex) with key commercialization milestones being met and this was seen at RDD 2022 held in Orlando Florida
Read more
HFA 152a: Roadmap to commercialization
Zephex® 152a – RDD 2022 Workshop presentation Click here: LINK Recorded for the RDD 2022 workshop May 1 With growing interest in the adoption of
Read more
Koura opens world’s first HFA 152a medical propellant production facility
• New HFA 152a production facility will produce low global warming potential (GWP) propellants for pressurised metered dose inhalers (pMDIs). • The new propellant will
Read more